Adjunctive with mTOR inhibitors, this approach could target source (mTOR hyperactivation) and symptom (microglia activation) of TSC brain malformations simultaneously and offer a valuable disease-modifying therapy. The gene discussed is MTOR; the disease is tuberous sclerosis.